Eli Lilly and Company is a global pharmaceutical company founded in 1876 by Colonel Eli Lilly in Indianapolis, Indiana. With nearly 150 years of operation and approximately 48,000 employees worldwide, the company focuses on discovering, developing, and manufacturing medicines across multiple therapeutic areas, including diabetes care and obesity treatments. The scale of operations spans drug discovery, clinical research and development, and pharmaceutical manufacturing - domains that generate significant data infrastructure, regulatory compliance requirements, and intellectual property protection needs.
The company's technical operations center on R&D-intensive processes including drug discovery pipelines, clinical trial management, and therapeutics development. This work requires handling sensitive patient data, proprietary research information, and regulated manufacturing systems across a global footprint. The pharmaceutical industry faces persistent threats from state-sponsored actors seeking IP theft, ransomware groups targeting healthcare infrastructure, and supply chain vulnerabilities in both physical and digital operations.
Eli Lilly operates under strict regulatory frameworks governing patient privacy, clinical trial data integrity, and pharmaceutical manufacturing standards. The company emphasizes scientific rigor and quality commitments dating to its founding - principles that extend to protecting research data, maintaining system availability for critical healthcare operations, and ensuring the integrity of drug development processes. The organization's patient-centered approach and global presence create complex security requirements spanning multiple jurisdictions, compliance regimes, and threat landscapes.